Technical Analysis for CLRB - Cellectar Biosciences, Inc.

Grade Last Price % Change Price Change
D 3.35 -3.74% -0.13
CLRB closed down 3.74 percent on Monday, March 18, 2024, on 24 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Pocket Pivot Bullish Swing Setup -3.74%
NR7 Range Contraction -3.74%
Inside Day Range Contraction -3.74%
Wide Bands Range Expansion -3.74%
Oversold Stochastic Weakness -3.74%
Stochastic Reached Oversold Weakness -0.89%
Wide Bands Range Expansion -0.89%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 9 hours ago
Down 3% about 9 hours ago
Possible NR7 about 10 hours ago
Fell Below Previous Day's Low about 14 hours ago
Down 2 % about 14 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cellectar Biosciences, Inc. Description

Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Imaging Oncology Stem Cell Radiation Chemotherapy Antineoplastic Drugs Occupational Safety And Health Blastoma Glioblastoma Radiation Therapy Targeted Therapy Advanced Solid Tumors Tomography Imaging Agent Positron Emission Tomography Cancer Stem Cell Cancer Stem Cells

Is CLRB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.45
52 Week Low 1.3
Average Volume 1,944,814
200-Day Moving Average 2.54
50-Day Moving Average 3.62
20-Day Moving Average 3.71
10-Day Moving Average 3.73
Average True Range 0.24
RSI (14) 40.83
ADX 27.95
+DI 21.80
-DI 20.47
Chandelier Exit (Long, 3 ATRs) 3.73
Chandelier Exit (Short, 3 ATRs) 3.96
Upper Bollinger Bands 4.35
Lower Bollinger Band 3.07
Percent B (%b) 0.22
BandWidth 34.65
MACD Line -0.01
MACD Signal Line 0.07
MACD Histogram -0.0801
Fundamentals Value
Market Cap 41.17 Million
Num Shares 12.3 Million
EPS -3.26
Price-to-Earnings (P/E) Ratio -1.03
Price-to-Sales 0.00
Price-to-Book 2.67
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.59
Resistance 3 (R3) 3.62 3.56 3.55
Resistance 2 (R2) 3.56 3.50 3.55 3.54
Resistance 1 (R1) 3.46 3.46 3.43 3.43 3.52
Pivot Point 3.40 3.40 3.39 3.39 3.40
Support 1 (S1) 3.30 3.34 3.27 3.27 3.18
Support 2 (S2) 3.24 3.30 3.23 3.16
Support 3 (S3) 3.14 3.24 3.15
Support 4 (S4) 3.11